{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T07:14:07Z","timestamp":1763018047215,"version":"3.37.3"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,7,5]],"date-time":"2019-07-05T00:00:00Z","timestamp":1562284800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,7,5]],"date-time":"2019-07-05T00:00:00Z","timestamp":1562284800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003478","name":"Ministry of Health, Labour and Welfare","doi-asserted-by":"publisher","award":["H29-nanchi-tou(nan)-ippan-021"],"award-info":[{"award-number":["H29-nanchi-tou(nan)-ippan-021"]}],"id":[{"id":"10.13039\/501100003478","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s13023-019-1148-8","type":"journal-article","created":{"date-parts":[[2019,7,5]],"date-time":"2019-07-05T14:02:48Z","timestamp":1562335368000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Evaluation of neurofibromatosis type 1 progression using a nationwide registry of patients who submitted claims for medical expense subsidies in Japan between 2008 and 2012"],"prefix":"10.1186","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5295-4082","authenticated-orcid":false,"given":"Takashi","family":"Yamauchi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Machi","family":"Suka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chikako","family":"Nishigori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroyuki","family":"Yanagisawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,7,5]]},"reference":[{"issue":"1","key":"1148_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2176\/nmc.st.2016-0135","volume":"57","author":"Y Kanatani","year":"2017","unstructured":"Kanatani Y, Tomita N, Sato Y, Eto A, Omoe H, Mizushima H. National registry of designated intractable diseases in Japan: present status and future prospects. Neurol Med Chir (Tokyo). 2017;57(1):1\u20137.","journal-title":"Neurol Med Chir (Tokyo)"},{"issue":"8","key":"1148_CR2","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1111\/j.1651-2227.2012.02705.x","volume":"101","author":"J Forman","year":"2012","unstructured":"Forman J, Taruscio D, Llera VA, Barrera LA, Cote TR, Edfjall C, et al. The need for worldwide policy and action plans for rare diseases. Acta Paediatr. 2012;101(8):805\u20137.","journal-title":"Acta Paediatr"},{"issue":"8","key":"1148_CR3","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1016\/S1474-4422(14)70063-8","volume":"13","author":"AC Hirbe","year":"2014","unstructured":"Hirbe AC, Gutmann DH. Neurofibromatosis type 1: a multidisciplinary approach to care. Lancet Neurol. 2014;13(8):834\u201343.","journal-title":"Lancet Neurol"},{"key":"1148_CR4","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/B978-0-444-62702-5.00004-4","volume":"132","author":"JL Anderson","year":"2015","unstructured":"Anderson JL, Gutmann DH. Neurofibromatosis type 1. Handb Clin Neurol. 2015;132:75\u201386.","journal-title":"Handb Clin Neurol"},{"issue":"1","key":"1148_CR5","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1001\/jama.1997.03550010065042","volume":"278","author":"DH Gutmann","year":"1997","unstructured":"Gutmann DH, Aylsworth A, Carey JC, Korf B, Marks J, Pyeritz RE, et al. The diagnostic evaluation and multidisciplinary management of neurofibromatosis 1 and neurofibromatosis 2. JAMA. 1997;278(1):51\u20137.","journal-title":"JAMA."},{"issue":"8","key":"1148_CR6","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1111\/1346-8138.12567","volume":"41","author":"K Tanito","year":"2014","unstructured":"Tanito K, Ota A, Kamide R, Nakagawa H, Niimura M. Clinical features of 58 Japanese patients with mosaic neurofibromatosis 1. J Dermatol. 2014;41(8):724\u20138.","journal-title":"J Dermatol"},{"issue":"11","key":"1148_CR7","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1111\/1346-8138.13902","volume":"44","author":"Y Ehara","year":"2017","unstructured":"Ehara Y, Yamamoto O, Kosaki K, Yoshida Y. Clinical severity in Japanese patients with neurofibromatosis 1 based on DNB classification. J Dermatol. 2017;44(11):1262\u20137.","journal-title":"J Dermatol"},{"issue":"2","key":"1148_CR8","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/j.cct.2012.12.002","volume":"34","author":"KJ Johnson","year":"2013","unstructured":"Johnson KJ, Hussain I, Williams K, Santens R, Mueller NL, Gutmann DH. Development of an international internet-based neurofibromatosis type 1 patient registry. Contemp Clin Trials. 2013;34(2):305\u201311.","journal-title":"Contemp Clin Trials"},{"issue":"1","key":"1148_CR9","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s13023-017-0756-4","volume":"13","author":"J Leppavirta","year":"2018","unstructured":"Leppavirta J, Kallionpaa RA, Uusitalo E, Vahlberg T, Poyhonen M, Peltonen J, et al. Congenital anomalies in neurofibromatosis 1: a retrospective register-based total population study. Orphanet J Rare Dis. 2018;13(1):5.","journal-title":"Orphanet J Rare Dis"},{"issue":"10","key":"1148_CR10","doi-asserted-by":"publisher","first-page":"2641","DOI":"10.1002\/ajmg.a.38372","volume":"173","author":"J Leppavirta","year":"2017","unstructured":"Leppavirta J, Kallionpaa RA, Uusitalo E, Vahlberg T, Poyhonen M, Timonen S, et al. The pregnancy in neurofibromatosis 1: a retrospective register-based total population study. Am J Med Genet A. 2017;173(10):2641\u20138.","journal-title":"Am J Med Genet A"},{"issue":"2","key":"1148_CR11","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1038\/bjc.2016.403","volume":"116","author":"E Uusitalo","year":"2017","unstructured":"Uusitalo E, Kallionpaa RA, Kurki S, Rantanen M, Pitkaniemi J, Kronqvist P, et al. Breast cancer in neurofibromatosis type 1: overrepresentation of unfavourable prognostic factors. Br J Cancer. 2017;116(2):211\u20137.","journal-title":"Br J Cancer"},{"issue":"17","key":"1148_CR12","doi-asserted-by":"publisher","first-page":"1978","DOI":"10.1200\/JCO.2015.65.3576","volume":"34","author":"E Uusitalo","year":"2016","unstructured":"Uusitalo E, Rantanen M, Kallionpaa RA, Poyhonen M, Leppavirta J, Yla-Outinen H, et al. Distinctive cancer associations in patients with neurofibromatosis type 1. J Clin Oncol. 2016;34(17):1978\u201386.","journal-title":"J Clin Oncol"},{"issue":"2","key":"1148_CR13","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1038\/sj.bjc.6603227","volume":"95","author":"L Walker","year":"2006","unstructured":"Walker L, Thompson D, Easton D, Ponder B, Ponder M, Frayling I, et al. A prospective study of neurofibromatosis type 1 cancer incidence in the UK. Br J Cancer. 2006;95(2):233\u20138.","journal-title":"Br J Cancer"},{"key":"1148_CR14","unstructured":"Japan Intractable Diseases Information Center. Japan Intractable Diseases Information Center [in Japanese]. \n                    http:\/\/www.nanbyou.or.jp\/\n                    \n                  . Accessed 30 Apr 2019."},{"key":"1148_CR15","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1001\/archneur.1988.00520290115023","volume":"45","author":"National Institute of Health Consenus Development Conference","year":"1988","unstructured":"National Institute of Health Consenus Development Conference. Neurofibromatosis conference statement. Arch Neurol. 1988;45:575\u20138.","journal-title":"Arch Neurol"},{"issue":"11","key":"1148_CR16","doi-asserted-by":"publisher","first-page":"2333","DOI":"10.1002\/jbmr.1685","volume":"27","author":"E Heerva","year":"2012","unstructured":"Heerva E, Koffert A, Jokinen E, Kuorilehto T, Peltonen S, Aro HT, et al. A controlled register-based study of 460 neurofibromatosis 1 patients: increased fracture risk in children and adults over 41 years of age. J Bone Miner Res. 2012;27(11):2333\u20137.","journal-title":"J Bone Miner Res"},{"issue":"12","key":"1148_CR17","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1017\/S0012162206002131","volume":"48","author":"SL Hyman","year":"2006","unstructured":"Hyman SL, Arthur Shores E, North KN. Learning disabilities in children with neurofibromatosis type 1: subtypes, cognitive profile, and attention-deficit-hyperactivity disorder. Dev Med Child Neurol. 2006;48(12):973\u20137.","journal-title":"Dev Med Child Neurol"},{"issue":"5","key":"1148_CR18","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1136\/adc.78.5.408","volume":"78","author":"MH Cnossen","year":"1998","unstructured":"Cnossen MH, de Goede-Bolder A, van den Broek KM, Waasdorp CM, Oranje AP, Stroink H, et al. A prospective 10 year follow up study of patients with neurofibromatosis type 1. Arch Dis Child. 1998;78(5):408\u201312.","journal-title":"Arch Dis Child"},{"issue":"5","key":"1148_CR19","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1136\/jmg.39.5.311","volume":"39","author":"DG Evans","year":"2002","unstructured":"Evans DG, Baser ME, McGaughran J, Sharif S, Howard E, Moran A. Malignant peripheral nerve sheath tumours in neurofibromatosis 1. J Med Genet. 2002;39(5):311\u20134.","journal-title":"J Med Genet"},{"issue":"6","key":"1148_CR20","doi-asserted-by":"publisher","first-page":"e0178639","DOI":"10.1371\/journal.pone.0178639","volume":"12","author":"M Seidlin","year":"2017","unstructured":"Seidlin M, Holzman R, Knight P, Korf B, Rangel Miller V, Viskochil D, et al. Characterization and utilization of an international neurofibromatosis web-based, patient-entered registry: an observational study. PLoS One. 2017;12(6):e0178639.","journal-title":"PLoS One"},{"issue":"4","key":"1148_CR21","doi-asserted-by":"publisher","first-page":"181","DOI":"10.5582\/irdr.2015.01043","volume":"4","author":"Y Sato","year":"2015","unstructured":"Sato Y, Nakatani E, Watanabe Y, Fukushima M, Nakashima K, Kannagi M, et al. Prediction of prognosis of ALS: importance of active denervation findings of the cervical-upper limb area and trunk area. Intractable Rare Dis Res. 2015;4(4):181\u20139.","journal-title":"Intractable Rare Dis Res"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-019-1148-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13023-019-1148-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-019-1148-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,3]],"date-time":"2020-07-03T23:10:44Z","timestamp":1593817844000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-019-1148-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,5]]},"references-count":21,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["1148"],"URL":"https:\/\/doi.org\/10.1186\/s13023-019-1148-8","relation":{},"ISSN":["1750-1172"],"issn-type":[{"type":"electronic","value":"1750-1172"}],"subject":[],"published":{"date-parts":[[2019,7,5]]},"assertion":[{"value":"17 December 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 June 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 July 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"We did not seek ethical approval for this study because it used a completely anonymous database of NF1 cases provided by the MHLW based on a legal foundation in Japan. The database did not include any personally identifiable information, such as names or addresses.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"166"}}